BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 10160098)

  • 1. Cost-effective policies for cervical cancer screening. An international review.
    Fahs MC; Plichta SB; Mandelblatt JS
    Pharmacoeconomics; 1996 Mar; 9(3):211-30. PubMed ID: 10160098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
    Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
    J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of the conventional papanicolaou test with a new adjunct to cytological screening for squamous cell carcinoma of the uterine cervix and its precursors.
    Taylor LA; Sorensen SV; Ray NF; Halpern MT; Harper DM
    Arch Fam Med; 2000 Aug; 9(8):713-21. PubMed ID: 10927709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.
    Karnon J; Peters J; Platt J; Chilcott J; McGoogan E; Brewer N
    Health Technol Assess; 2004 May; 8(20):iii, 1-78. PubMed ID: 15147611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative cost-effectiveness of HPV vaccines in the prevention of cervical cancer in Malaysia.
    Ezat SW; Aljunid S
    Asian Pac J Cancer Prev; 2010; 11(4):943-51. PubMed ID: 21133606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cost-effectiveness of a cervical cancer screening programme in the Algarve region, Portugal].
    Novoa Vázquez RM
    Rev Esp Salud Publica; 2004; 78(3):341-53. PubMed ID: 15293955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of cervical cancer screening: comparison of screening policies.
    van den Akker-van Marle ME; van Ballegooijen M; van Oortmarssen GJ; Boer R; Habbema JD
    J Natl Cancer Inst; 2002 Feb; 94(3):193-204. PubMed ID: 11830609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing.
    Brown AD; Garber AM
    JAMA; 1999 Jan; 281(4):347-53. PubMed ID: 9929088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cervical cancer screening programme in Norway, 1992-2000: changes in Pap smear coverage and incidence of cervical cancer.
    Nygård JF; Skare GB; Thoresen SØ
    J Med Screen; 2002; 9(2):86-91. PubMed ID: 12133929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of patient adherence and test performance on the cost-effectiveness of cervical cancer screening in developing countries: the case of Honduras.
    Perkins RB; Langrish SM; Stern LJ; Burgess JF; Simon CJ
    Womens Health Issues; 2010; 20(1):35-42. PubMed ID: 19944623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cervical cancer screening program of Paraná: cost-effective model in a developing country.
    Bleggi Torres LF; Werner B; Totsugui J; Collaço LM; Araújo SR; Huçulak M; Boza EJ; Fischer RM; De Laat L; Sobbania LC; Raggio A
    Diagn Cytopathol; 2003 Jul; 29(1):49-54. PubMed ID: 12827718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Costs of population cervical cancer screening program in Poland between 2007-2009].
    Spaczyński M; Karowicz-Bilinska A; Kedzia W; Molińska-Glura M; Seroczyński P; Januszek-Michalecka L; Rokita W; Nowak-Markwitz E
    Ginekol Pol; 2010 Oct; 81(10):750-6. PubMed ID: 21117303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effective analysis of recall methods for cervical cancer screening in Selangor--results from a prospective randomized controlled trial.
    Rashid RM; Ramli S; John J; Dahlui M
    Asian Pac J Cancer Prev; 2014; 15(13):5143-7. PubMed ID: 25040965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cervical cancer screening in the United States and the Netherlands: a tale of two countries.
    Habbema D; De Kok IM; Brown ML
    Milbank Q; 2012 Mar; 90(1):5-37. PubMed ID: 22428690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost effectiveness of cervical cancer screening strategies in Tunisia].
    Hsaïri M; Fakhfakh R; Ghyoula M; Ben Abdallah M; Achour N
    Tunis Med; 2000 Oct; 78(10):557-61. PubMed ID: 11190738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro conventional cytology historical strengths and current limitations.
    Spitzer M
    Obstet Gynecol Clin North Am; 2002 Dec; 29(4):673-83. PubMed ID: 12509091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of cervical cancer screening and follow-up programs.
    Celentano DD; deLissovoy G
    Public Health Rev; 1989-1990; 17(2-3):173-240. PubMed ID: 2518819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan.
    Koong SL; Yen AM; Chen TH
    J Med Screen; 2006; 13 Suppl 1():S44-7. PubMed ID: 17227642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
    Suba EJ; Nguyen CH; Nguyen BD; Raab SS;
    Cancer; 2001 Mar; 91(5):928-39. PubMed ID: 11251944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of cervical cancer with screening programme in Branicevo District and cost-effectiveness analysis adjusted to the territory of the Republic of Serbia.
    Perovic S
    J BUON; 2009; 14(1):93-6. PubMed ID: 19373953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.